Baudax Bio
Baudax Bio is a public specialty pharmaceutical company commercializing ANJESO, a hospital-use NSAID, while developing the acquired TI-168 TCR-Treg cell therapy platform for Hemophilia A patients with factor VIII inhibitors.
- Company typePublic
- Founded2015
- HeadquartersMalvern, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Baudax Bio firmographics
Firmographics- Name
- Baudax Bio
- Legal name
- Baudax Bio, Inc.
- Website
- https://baudaxbio.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Baudax Bio is a public specialty pharmaceutical company commercializing ANJESO, a hospital-use NSAID, while developing the acquired TI-168 TCR-Treg cell therapy platform for Hemophilia A patients with factor VIII inhibitors.
- Ownership category
- akta.pro rank
Where Baudax Bio is headquartered
LocationHeadquarters
- HQ city
- Malvern
- HQ country
- United States
- HQ region
- North America
Markets served
Baudax Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Revenue model
- Product Sales (ANJESO): Revenue generated from the commercialization of ANJESO, a marketed NSAID product targeted at hospital use.
- Pipeline Development: Ongoing development of clinical-stage assets funded through capital raises, with proceeds allocated to working capital, pipeline advancement, and general corporate purposes.
Baudax Bio product offering
Product offeringCore offering
Baudax Bio is a specialty pharmaceutical company that develops and commercializes innovative products for acute care settings. Its commercially available product is ANJESO, an NSAID used for post-operative pain management in hospitals. The company is also developing a clinical-stage pipeline, led by the TI-168 autologous FVIII TCR-Treg cell therapy acquired from TeraImmune for treating Hemophilia A patients with clotting factor VIII inhibitors.
Differentiator
Problem solved
Functional benefit
Brands
- ANJESO: Marketed NSAID product for hospital use
Products and services
- ANJESO A marketed NSAID (Non-Steroidal Anti-Inflammatory Drug) designed for hospital use, targeting post-operative pain management in acute care settings for surgical inpatients.
- TI-168 A clinical-stage autologous FVIII TCR-Treg cell therapy asset acquired from TeraImmune, designed to treat Hemophilia A patients who have developed clotting factor VIII inhibitors.
Companies that use Baudax Bio
Customer profileSegments1 record
Ideal customer profiles1 record
Baudax Bio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Baudax Bio partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor and core.
- AES Clean Technology Inc.minorAES Clean Technology Inc. introduced the Cleanlock module, a modular cleanroom airlock system designed to support pharmaceutical manufacturing quality control. Referenced in a market analysis covering Baudax Bio's therapeutic area. No direct commercial relationship with Baudax Bio is described.
- TeraImmune, Inc.coreBaudax Bio completed the acquisition of TeraImmune, Inc. in June 2023, bringing the TI-168 autologous FVIII TCR-Treg cell therapy asset into Baudax's pipeline. The acquisition is intended to capitalize on T-cell Receptor (TCR)-Treg cell therapy platform for Hemophilia A patients with inhibitors. This acquisition represents the company's entry into the cell therapy space for rare bleeding disorders.
Scale indicators7 records
Baudax Bio competitors and assessment
Company assessmentEmerging players
Direct peers
- Sonoma Biotherapeutics: Clinical-stage biotech developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases. Directly comparable to Baudax Bio's TCR-Treg platform as a peer in the emerging Treg cell therapy space with proprietary engineered Treg technology.
- Pacira BioSciences: Specialty hospital-focused pharmaceutical company marketing EXPAREL, a long-acting postsurgical pain product. Directly comparable to Baudax Bio's ANJESO business in targeting hospital-based post-operative pain management through differentiated, hospital-channel therapeutics.
- Sangamo Therapeutics: Clinical-stage gene and cell therapy company with a Hemophilia A program (and other rare-disease assets). Directly comparable on the TI-168 side as a small-cap developer of novel therapies for Hemophilia A patients with inhibitors, using advanced biologic modalities.
- Heron Therapeutics: Specialty pharma developing HTX-011 and other hospital/postoperative pain therapeutics. Closely comparable to Baudax Bio as a small-cap, hospital-channel pain management company with a marketed product and pipeline challenges typical of the segment.
- GentiBio: Emerging engineered Treg cell therapy company developing autologous and allogeneic Tregs for autoimmune and inflammatory indications. Directly comparable to Baudax Bio on the TCR-Treg platform side, given both companies are pursuing Treg-based cell therapies for immune-mediated disease.
Broad incumbents
- Pfizer: Large pharmaceutical company with multiple Hemophilia A and broader hematology assets through its rare-disease portfolio. Comparable as a dominant incumbent in the Hemophilia A treatment market relevant to TI-168.
- Mallinckrodt: Specialty pharmaceutical company with a hospital-focused portfolio including analgesics and other acute-care products. Comparable to Baudax Bio's hospital-channel commercial positioning and acute-care specialty pharma orientation.
- BioMarin Pharmaceutical: Established rare-disease biotech with a marketed/recently approved Hemophilia A gene therapy (ROCTAVIAN) and broader hematology franchise. Comparable as a major Hemophilia A therapeutics player addressing the same patient population that TI-168 targets.
Others
- Tarsus Pharmaceuticals: Small-cap specialty pharmaceutical company commercializing a single differentiated therapy in a focused therapeutic area. Comparable to Baudax Bio as a publicly traded, narrowly focused specialty pharma with a single marketed asset and limited pipeline diversification.
Market position
Customer concentration
Baudax Bio social profiles
Digital presenceBaudax Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Baudax Bio leadership team
Management profileNumber of profiles
Profiles3 records
Baudax Bio subsidiaries and ownership
Company hierarchySubsidiaries1 record
Baudax Bio funding detail
Funding detailFunding overview
Funding rounds9 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Baudax Bio M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Baudax Bio
What does Baudax Bio do?
Baudax Bio is a specialty pharmaceutical company that develops and commercializes innovative products for acute care settings. Its commercially available product is ANJESO, an NSAID used for post-operative pain management in hospitals. The company is also developing a clinical-stage pipeline, led by the TI-168 autologous FVIII TCR-Treg cell therapy acquired from TeraImmune for treating Hemophilia A patients with clotting factor VIII inhibitors.
Is Baudax Bio a public or private company?
Baudax Bio is a public company. It is classified as public and is currently operating.
When was Baudax Bio founded?
Baudax Bio was founded in 2015. It employs 51 to 100 people.
Where is Baudax Bio based?
Baudax Bio is headquartered in Malvern, United States, in the North America region.
How does Baudax Bio make money?
Two revenue lines are on record. Product Sales (ANJESO) is the primary driver. The others are pipeline Development.
Who are Baudax Bio's main competitors?
Quell Therapeutics is listed as an emerging player. Direct peers are Sonoma Biotherapeutics, Pacira BioSciences, Sangamo Therapeutics, Heron Therapeutics and GentiBio. Broad incumbents are Pfizer, Mallinckrodt and BioMarin Pharmaceutical. Tarsus Pharmaceuticals is listed as an others.
Does Baudax Bio have an API?
No public API is recorded for Baudax Bio.